Sign in or Register   Sign in or Register
  |  

Rabbit Anti-CSGALNACT1 Recombinant Antibody (EG844) (CBMAB-EN1009-LY)

The product is antibody recognizes CSGALNACT1. The antibody EG844 immunoassay techniques such as: IHC: 1:50~1:100 ELISA: 1:10000.
See all CSGALNACT1 antibodies

Summary

Host Animal
Rabbit
Specificity
Human, Mouse, Rat
Clone
EG844
Antibody Isotype
IgG
Application
IHC: 1:50~1:100 ELISA: 1:10000

Basic Information

Immunogen
The antibody was produced against synthesized peptide derived from internal of human CSGALNACT1.
Specificity
Human, Mouse, Rat
Antibody Isotype
IgG
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1
Introduction
CSGALNACT1 (Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1) is a Protein Coding gene. Diseases associated with CSGALNACT1 include Multiple Sclerosis. Among its related pathways are Glycosaminoglycan metabolism and Metabolism. Gene Ontology (GO) annotations related to this gene include glucuronosyltransferase activity and glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity. An important paralog of this gene is CSGALNACT2.
Entrez Gene ID
Human55790
Mouse234356
Rat306375
UniProt ID
HumanQ8TDX6
MouseQ8BJQ9
RatB5DEY9
Alternative Names
Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1; Glucuronylgalactosylproteoglycan 4-Beta-N- Acetylgalactosaminyltransferase; Chondroitin Beta-1,4-N-Acetylgalactosaminyltransferase 1; Chondroitin Beta1,4 N-Acetylgalactosaminyltransferase; Beta4GalNAcT-1; CSGalNAcT-1;
Function
Transfers 1,4-N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the non-reducing end of glucuronic acid (GlcUA). Required for addition of the first GalNAc to the core tetrasaccharide linker and for elongation of chondroitin chains. Important role in chondroitin chain biosynthesis in cartilage formation and subsequent endochondral ossification (PubMed:11788602, PubMed:12163485, PubMed:12446672, PubMed:17145758, PubMed:31705726).

Moreover, is involved in the metabolism of aggrecan (By similarity).
Biological Process
Cartilage development Source: Ensembl
Chondroitin sulfate biosynthetic process Source: UniProtKB
Chondroitin sulfate proteoglycan biosynthetic process Source: UniProtKB
Chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process Source: UniProtKB
Dermatan sulfate proteoglycan biosynthetic process Source: UniProtKB
Endochondral ossification Source: Ensembl
Extracellular matrix organization Source: Ensembl
Heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process Source: UniProtKB
Heparin biosynthetic process Source: UniProtKB
Proteoglycan biosynthetic process Source: UniProtKB
UDP-glucuronate metabolic process Source: UniProtKB
UDP-N-acetylgalactosamine metabolic process Source: UniProtKB
Cellular Location
Golgi stack membrane
Involvement in disease
Skeletal dysplasia, mild, with joint laxity and advanced bone age (SDJLABA):
An autosomal recessive disorder characterized by skeletal dysplasia, short stature, short long bones, advanced bone age, joint laxity, and facial dysmorphism.
Topology
Cytoplasmic: 1-14
Helical: 15-35
Lumenal: 36-532
PTM
N-glycosylated.

Inada, R., Miyamoto, K., Tanaka, N., Moriguchi, K., Kadomatsu, K., Takeuchi, K., ... & Kusunoki, S. (2021). Chondroitin sulfate N-acetylgalactosyltransferase-1 knockout shows milder phenotype in experimental autoimmune encephalomyelitis than in wild type. Glycobiology, 31(3), 260-265.

Meyer, R., Schacht, S., Buschmann, L., Begemann, M., Kraft, F., Haag, N., ... & Elbracht, M. (2019). Biallelic CSGALNACT1-mutations cause a mild skeletal dysplasia. Bone, 127, 446-451.

Ida-Yonemochi, H., Morita, W., Sugiura, N., Kawakami, R., Morioka, Y., Takeuchi, Y., ... & Takeuchi, K. (2018). Craniofacial abnormality with skeletal dysplasia in mice lacking chondroitin sulfate N-acetylgalactosaminyltransferase-1. Scientific reports, 8(1), 1-15.

Sakai, D., Nakai, T., Hiraishi, S., Nakamura, Y., Ando, K., Naiki, M., & Watanabe, M. (2018). Upregulation of glycosaminoglycan synthesis by Neurotropin in nucleus pulposus cells via stimulation of chondroitin sulfate N-acetylgalactosaminyltransferase 1: a new approach to attenuation of intervertebral disc degeneration. PloS one, 13(8), e0202640.

Shimbo, M., Suzuki, R., Fuseya, S., Sato, T., Kiyohara, K., Hagiwara, K., ... & Takahashi, S. (2017). Postnatal lethality and chondrodysplasia in mice lacking both chondroitin sulfate N-acetylgalactosaminyltransferase-1 and-2. PLoS One, 12(12), e0190333.

Vodopiutz, J., Mizumoto, S., Lausch, E., Rossi, A., Unger, S., Janocha, N., ... & Janecke, A. R. (2017). Chondroitin sulfate N‐acetylgalactosaminyltransferase‐1 (CSGalNAcT‐1) deficiency results in a mild skeletal dysplasia and joint laxity. Human mutation, 38(1), 34-38.

Yoshioka, N., Miyata, S., Tamada, A., Watanabe, Y., Kawasaki, A., Kitagawa, H., ... & Igarashi, M. (2017). Abnormalities in perineuronal nets and behavior in mice lacking CSGalNAcT1, a key enzyme in chondroitin sulfate synthesis. Molecular brain, 10(1), 1-10.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Rabbit Anti-CSGALNACT1 Recombinant Antibody (EG844)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare